Press Releases

Third Major Release in 2024 Marks Dramatic Improvements In Indoor Navigation & Mapping

TORONTO, ON / ACCESSWIRE / May 14, 2024 / ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB: ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce the launch of ARway V3.1, a major update to its spatial computing... (continue reading...)

TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V:ENTG) (OTCQX: ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products announced today it will file its first quarter 2024 financial statements and management’s discussion and analysis after market close on Monday, May 27, 2024. Entourage will host a conference call the following day on Tuesday, May 28, 2024, at 10:00 am... (continue reading...)

TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (“NowVertical” or the “Company”) (TSX-V: NOW) (OTCQB: NOWVF), is pleased to announce the appointment of David Doritty, who currently serves as the Vice-Chair at Echelon Wealth Partners, as an independent director on NowVertical’s board of directors.

"We warmly welcome David Doritty as he joins our board," stated Elaine Kunda, Chair of NowVertical’s Board. "His expertise in capital markets,... (continue reading...)

– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months –

– Topline data expected in early 2025 –

– Breakthrough Therapy Designation to enable expedited review by FDA –

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has completed enrollment of... (continue reading...)

- PDUFA target action date of November 13, 2024 -

WARREN, N.J., May 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.

"We are excited to be one step closer to... (continue reading...)